

Claims:

1. A monoclonal antibody or antigen-binding fragment thereof that specifically bind to the TRBV-9 family beta-chain region of the human T cell receptor, comprising a heavy chain variable domain, the amino acid sequence of which is shown in SEQ ID No: 16 and a light chain variable domain, the amino acid sequence of which is shown in SEQ ID No: 18.
2. A monoclonal antibody according to Claim 1, which includes a heavy chain having the amino acid sequence of SEQ ID No: 20 and a light chain having the amino acid sequence of SEQ ID No: 22.
3. A monoclonal antibody according to any of Claims 2, which is a full-length IgG antibody.
4. A nucleic acid that encodes a monoclonal antibody or antigen-binding fragment thereof according to any of Claims 1-3, wherein the antibody or antigen binding fragment thereof specifically binds to the TRBV9 family beta-chain region of the human T receptor.
5. An expression vector containing a nucleic acid according to Claim 4.
6. A method of obtaining a host cell for producing an antibody or antigen-binding fragment thereof according to any of Claims 1-3 comprising co-transformation of a cell with a vector according to Claim 5.
7. A host cell for obtaining an antibody or antigen-binding fragment thereof according to any of Claims 1-3 comprising a nucleic acid according to Claim 4.
8. A method of obtaining an antibody or antigen-binding fragment thereof according to any of Claims 1-3, comprising culturing a host cell according to Claim 7 in a culture medium under conditions ensuring the production of said antibody, followed by isolation and purification of the obtained antibody.

9. A pharmaceutical composition, comprising in a therapeutically effective amount an antibody or antigen-binding fragment thereof according to any of Claims 1-3 in combination with one or more pharmaceutically acceptable excipients.

10. A pharmaceutical composition, containing in a therapeutically effective amount an antibody or antigen-binding fragment thereof according to any of Claims 1-3 and at least in a therapeutically effective amount of one other therapeutically active compound.

11. The pharmaceutical composition according to Claim 10, wherein the other therapeutically active compound is selected from a small molecule, antibody or steroid hormones.

12. The antibody or antigen-binding fragment thereof according to any of Claims 1-3 or a pharmaceutical composition according to any of Claims 9-11 for preventing or treating a disease or disorder mediated by the human T cell receptor bearing the TRBV9 family beta-chain, wherein the disease is selected from the group: ankylosing spondylitis, celiac disease, T cell leukemia, T cell lymphoma.